Novartis Posts New Data Reinforcing Efficacy, Convenience Of Cosentyx Autoinjector In Psoriasis

Novartis AG NVS announced data from an international Phase 3b study of Cosentyx (secukinumab) in plaque psoriasis.
Data showed that treatment with Cosentyx 300 mg in a 2 mL autoinjector (UnoReady pen) resulted in high efficacy and convenient administration.
The data were presented at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress.
The MATURE study was assessed using a Cosentyx 300 mg autoinjector versus two 150 mg pre-filled syringes or a placebo.
Patients using the 300 mg autoinjector reported significantly improved skin clearance measured by Psoriasis Area and Severity Index (PASI) 75 and 90 versus placebo.
The study showed high patient satisfaction, with 100% of those in the Cosentyx 300 mg UnoReady group reporting they were “very satisfied” or “satisfied” at Week 28.
The safety profile reported was consistent with previous studies, and no new safety signals were observed1.
The UnoReady pen was approved for use in Europe in November 2020 for all patients requiring a 300 mg dose of Cosentyx.
Price Action: NVS stock is up 0.49% at $82.70 during the premarket session on the last check Wednesday.

Overview Rating:

Speculative

0100